Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Voriconazole

FDA-approved product (tablet, oral), marketed as Vfend, Voriconazole.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Voriconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Bacterial Infections and Mycoses
  • Candidemia
  • Candidiasis
  • Fungal infectious disease
  • Fusariosis
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC03; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Voriconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Voriconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Influence of CYP2C19 Genotype on Safety and Efficacy of Voriconazole in Pediatric Patients With Hematologic Malignancy

    NCT04743544 · start 2019-11-01

    Registered record
    Registry ID
    NCT04743544
    Conditions
    Adverse Drug Reactions
    Interventions
    Voriconazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-11-01
    Completion
    2022-10-31
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Drug Reactions
    InterventionVoriconazole
    PhaseNot recorded
    Registry statusUnknown

  • CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels

    NCT03731169 · start 2018-01-10

    Registered record
    Registry ID
    NCT03731169
    Conditions
    Aspergillosis Invasive; Fungal Infection
    Interventions
    Voriconazole genotype-specific dosing; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-01-10
    Completion
    2020-08-28
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspergillosis Invasive; Fungal Infection
    InterventionVoriconazole genotype-specific dosing; Standard of Care
    PhasePhase 4
    Registry statusCompleted

  • Impact of Genotyping P450 2C19 on Hospitalization Period

    NCT03554239 · start 2016-12

    Registered record
    Registry ID
    NCT03554239
    Conditions
    Infection
    Interventions
    genotyping
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2016-12
    Completion
    2017-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    Interventiongenotyping
    PhaseNot applicable
    Registry statusWithdrawn

  • Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers

    NCT02731638 · start 2016-09

    Registered record
    Registry ID
    NCT02731638
    Conditions
    Corneal Ulcer; Fungal Keratitis
    Interventions
    Intrastromal voriconazole; Natamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-09
    Completion
    2018-07
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Ulcer; Fungal Keratitis
    InterventionIntrastromal voriconazole; Natamycin
    PhasePhase 3
    Registry statusCompleted

  • The Study of Voriconazole Trough Level in the First Two Weeks After Administration in King Chulalongkorn Memorial Hospital.

    NCT03260634 · start 2016-01-01

    Registered record
    Registry ID
    NCT03260634
    Conditions
    Voriconazole; Fungal Infection
    Interventions
    Voriconazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2016-01-01
    Completion
    2018-01-01
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVoriconazole; Fungal Infection
    InterventionVoriconazole
    PhaseNot recorded
    Registry statusUnknown

  • Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration

    NCT02396225 · start 2015-03

    Registered record
    Registry ID
    NCT02396225
    Conditions
    Invasive Aspergillosis
    Interventions
    Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2015-03
    Completion
    2016-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Aspergillosis
    InterventionVoriconazole
    PhaseNot applicable
    Registry statusTerminated

  • Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients

    NCT03067350 · start 2015-01

    Registered record
    Registry ID
    NCT03067350
    Conditions
    Invasive Aspergillosis; Haematological Cancer Patients; Voriconazole
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-01
    Completion
    2019-01
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Aspergillosis; Haematological Cancer Patients; Voriconazole
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients

    NCT02100761 · start 2014-06

    Registered record
    Registry ID
    NCT02100761
    Conditions
    Invasive Pulmonary Aspergillosis
    Interventions
    Voriconazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2014-06
    Completion
    2015-06
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Pulmonary Aspergillosis
    InterventionVoriconazole
    PhaseNot recorded
    Registry statusUnknown

  • Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

    NCT02014558 · start 2013-10-09

    Registered record
    Registry ID
    NCT02014558
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Gilteritinib; Voriconazole; Midazolam; Cephalexin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-10-09
    Completion
    2018-03-07
    Enrolment
    265

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionGilteritinib; Voriconazole; Midazolam; Cephalexin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis

    NCT01621321 · start 2013-06

    Registered record
    Registry ID
    NCT01621321
    Conditions
    Allergic Bronchopulmonary Aspergillosis
    Interventions
    Prednisolone; Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2013-06
    Completion
    2016-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Bronchopulmonary Aspergillosis
    InterventionPrednisolone; Voriconazole
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects

    NCT01787032 · start 2013-01

    Registered record
    Registry ID
    NCT01787032
    Conditions
    Healthy
    Interventions
    BI 113608; BI 113608; BI 113608; Ketoconazole; Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-01
    Completion
    2013-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBI 113608; BI 113608; BI 113608; Ketoconazole +1 more
    PhasePhase 1
    Registry statusCompleted

  • Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents

    NCT01976078 · start 2012-09

    Registered record
    Registry ID
    NCT01976078
    Conditions
    Pharmacokinetics; Voriconazole
    Interventions
    Midazolam/Ranitidine/Esomeprazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-09
    Completion
    2015-04-22
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics; Voriconazole
    InterventionMidazolam/Ranitidine/Esomeprazole
    PhaseNot recorded
    Registry statusCompleted

  • Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)

    NCT02366884 · start 2011-07-26

    Registered record
    Registry ID
    NCT02366884
    Conditions
    Neoplasms
    Interventions
    Anti-Bacterial Agents; Anti-Fungal Agents; Anti-Protozoal Agents
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-07-26
    Completion
    2023-12-31
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionAnti-Bacterial Agents; Anti-Fungal Agents; Anti-Protozoal Agents
    PhasePhase 2
    Registry statusUnknown

  • The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo

    NCT00997035 · start 2010-05

    Registered record
    Registry ID
    NCT00997035
    Conditions
    Corneal Ulcer; Eye Infections, Fungal
    Interventions
    Voriconazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-05
    Completion
    2016-03
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Ulcer; Eye Infections, Fungal
    InterventionVoriconazole; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study of Cyclodextrin (SBECD) and Voriconazole Blood Concentrations During Continuous Dialysis

    NCT01101386 · start 2010-05

    Registered record
    Registry ID
    NCT01101386
    Conditions
    Fungal Infection
    Interventions
    Voriconazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-05
    Completion
    2012-11
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Infection
    InterventionVoriconazole
    PhaseNot recorded
    Registry statusCompleted